Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Investigation of LRRC8-Mediated Volume-Regulated Anion Currents in Xenopus Oocytes

  • Gaitan Peñas, Hector|||0000-0001-9797-903X
  • Gradogna, Antonella
  • Laparra-Cuervo, Lara
  • Solsona, Carles
  • Fernández-Dueñas, Víctor|||0000-0001-7834-2965
  • Barrallo Gimeno, Alejandro|||0000-0003-2086-8926
  • Ciruela, Francisco|||0000-0003-0832-3739
  • Lakadamyali, Melike
  • Estévez, Raúl|||0000-0003-1579-650X
Volume-regulated anion channels (VRACs) play an important role in controlling cell volume by opening upon cell swelling. Recent work has shown that heteromers of LRRC8A with other LRRC8 members (B, C, D, and E) form the VRAC. Here, we used Xenopus oocytes as a simple system to study LRRC8 proteins. We discovered that adding fluorescent proteins to the C-terminus resulted in constitutive anion channel activity. Using these constructs, we reproduced previous findings indicating that LRRC8 heteromers mediate anion and osmolyte flux with subunit-dependent kinetics and selectivity. Additionally, we found that LRRC8 heteromers mediate glutamate and ATP flux and that the inhibitor carbenoxolone acts from the extracellular side, binding to probably more than one site. Our results also suggest that the stoichiometry of LRRC8 heteromers is variable, with a number of subunits ≥6, and that the heteromer composition depends on the relative expression of different subunits. The system described here enables easy structure-function analysis of LRRC8 proteins.
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Optical control of pain in vivo with a photoactive mGlu5 receptor negative allosteric modulator

  • Nonell, Santi
  • Bresolí-Obach, Roger
  • Font Inglès, Joan
  • López-Cano, Marc
  • Notartomaso, Serena
  • Scarselli, Pamela
  • Di Pietro, Paola
  • Battaglia, Giuseppe
  • Malhaire, Fanny
  • Rovira, Xavier
  • Catena, Juanlo
  • Giraldo, Jesús
  • Pin, Jean-Philippe
  • Fernández-Dueñas, Víctor
  • Goudet, Cyril
  • Nicoletti, Ferdinando
  • Llebaria, Amadeu
  • Ciruela, Francisco
Light-operated drugs constitute a major target in drug discovery, since they may provide spatiotemporal resolution for the treatment of complex diseases (i.e. chronic pain). JF-NP-26 is an inactive photocaged derivative of the metabotropic glutamate type 5 (mGlu5) receptor negative allosteric modulator raseglurant. Violet light illumination of JF-NP-26 induces a photochemical reaction prompting the active-drug’s release, which effectively controls mGlu5 receptor activity both in ectopic expressing systems and in striatal primary neurons. Systemic administration in mice followed by local light-emitting diode (LED)-based illumination, either of the thalamus or the peripheral tissues, induced JF-NP-26-mediated light-dependent analgesia both in neuropathic and in acute/tonic inflammatory pain models. These data offer the first example of optical control of analgesia in vivo using a photocaged mGlu5 receptor negative allosteric modulator. This approach shows potential for precisely targeting, in time and space, endogenous receptors, which may allow a better management of difficult-to-treat disorders.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Cognitive impairments associated with alterations in synaptic proteins induced by the genetic loss of adenosine A 2A receptors in mice

  • Moscoso-Castro, Maria
  • López-Cano, Marc
  • Gracia-Rubio, Irene
  • Ciruela, Francisco
  • Valverde, Olga
The study of psychiatric disorders usually focuses on emotional symptoms assessment. However, cognitive deficiencies frequently constitute the core symptoms, are often poorly controlled and handicap individual's quality of life. Adenosine receptors, through the control of both dopamine and glutamate systems, have been implicated in the pathophysiology of several psychiatric disorders such as schizophrenia and attention deficit/hyperactivity disorder. Indeed, clinical data indicate that poorly responsive schizophrenia patients treated with adenosine adjuvants show improved treatment outcomes. The A2A adenosine receptor subtype (A2AR) is highly expressed in brain areas controlling cognition and motivational responses including the striatum, hippocampus and cerebral cortex. Accordingly, we study the role of A2AR in the regulation of cognitive processes based on a complete cognitive behavioural analysis coupled with the assessment of neurogenesis and sub-synaptic protein expression in adult and middle-aged A2AR constitutional knockout mice and wild-type littermates. Our results show overall cognitive impairments in A2AR knockout mice associated with a decrease in new-born hippocampal neuron proliferation and concomitant changes in synaptic protein expression, in both the prefrontal cortex and the hippocampus. These results suggest a deficient adenosine signalling in cognitive processes, thus providing new opportunities for the therapeutic management of cognitive deficits associated with psychiatric disorders.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Optical control of pain in vivo with a photoactive mGlu5 receptor negative allosteric modulator

  • Nonell, Santi
  • Bresolí-Obach, Roger
  • Font Inglès, Joan
  • López-Cano, Marc
  • Notartomaso, Serena
  • Scarselli, Pamela
  • Di Pietro, Paola
  • Battaglia, Giuseppe
  • Malhaire, Fanny
  • Rovira, Xavier
  • Catena, Juanlo
  • Giraldo, Jesús
  • Pin, Jean-Philippe
  • Fernández-Dueñas, Víctor
  • Goudet, Cyril
  • Nicoletti, Ferdinando
  • Llebaria, Amadeu
  • Ciruela, Francisco
Light-operated drugs constitute a major target in drug discovery, since they may provide spatiotemporal resolution for the treatment of complex diseases (i.e. chronic pain). JF-NP-26 is an inactive photocaged derivative of the metabotropic glutamate type 5 (mGlu5) receptor negative allosteric modulator raseglurant. Violet light illumination of JF-NP-26 induces a photochemical reaction prompting the active-drug’s release, which effectively controls mGlu5 receptor activity both in ectopic expressing systems and in striatal primary neurons. Systemic administration in mice followed by local light-emitting diode (LED)-based illumination, either of the thalamus or the peripheral tissues, induced JF-NP-26-mediated light-dependent analgesia both in neuropathic and in acute/tonic inflammatory pain models. These data offer the first example of optical control of analgesia in vivo using a photocaged mGlu5 receptor negative allosteric modulator. This approach shows potential for precisely targeting, in time and space, endogenous receptors, which may allow a better management of difficult-to-treat disorders.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Illuminating phenylazopyridines to photoswitch metabotropic glutamate receptors, from the flask to the animals

  • Gómez-Santacana, Xavier|||0000-0001-8830-0494
  • Pittolo, Silvia|||0000-0002-5673-1692
  • Rovira, Xavier|||0000-0002-9764-9927
  • Lopez, Marc
  • Zussy, Charleine
  • Dalton, James A. R.|||0000-0002-5279-4581
  • Faucherre, Adèle
  • Jopling, Chris
  • Pin, Jean-Philippe|||0000-0002-1423-345X
  • Ciruela, Francisco|||0000-0003-0832-3739
  • Goudet, Cyril|||0000-0002-8255-3535
  • Giraldo, Jesús|||0000-0001-7082-4695
  • Gorostiza, Pau|||0000-0002-7268-5577
  • Llebaria, Amadeu|||0000-0002-8200-4827
Phenylazopyridines are photoisomerizable compounds with high potential to control biological functions with light. We have obtained a series of phenylazopyridines with light dependent activity as negative allosteric modulators (NAM) of metabotropic glutamate receptor subtype 5 (mGlu). Here we describe the factors needed to achieve an operational molecular photoisomerization and its effective translation into in vitro and in vivo receptor photoswitching, which includes zebrafish larva motility and the regulation of the antinociceptive effects in mice. The combination of light and some specific phenylazopyridine ligands displays atypical pharmacological profiles, including light-dependent receptor overactivation, which can be observed both in vitro and in vivo. Remarkably, the localized administration of light and a photoswitchable compound in the peripheral tissues of rodents or in the brain amygdalae results in an illumination-dependent analgesic effect. The results reveal a robust translation of the phenylazopyridine photoisomerization to a precise photoregulation of biological activity. The cis - trans photoisomerization of phenylazopyridines, allowing mGlu receptor activity photoswitching in cells, is used in vivo to control zebrafish motility with light and analgesia in mice including peripheral and brain localized illumination.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Optical control of pain in vivo with a photoactive mGlu receptor negative allosteric modulator

  • Font Inglès, Joan|||0000-0001-8416-1909
  • López Cano, Marc|||0000-0001-8885-3726
  • Notartomaso, Serena|||0000-0003-4374-9233
  • Scarselli, Pamela|||0000-0002-4245-0849
  • Di Pietro, Paola|||0000-0003-1327-1961
  • Bresolí-Obach, Roger|||0000-0002-7819-7750
  • Battaglia, Giuseppe|||0000-0001-7571-3417
  • Malhaire, Fanny
  • Rovira, Xavier|||0000-0002-9764-9927
  • Catena, Juanlo|||0000-0002-2423-5926
  • Giraldo, Jesús|||0000-0001-7082-4695
  • Pin, Jean-Philippe|||0000-0002-1423-345X
  • Fernández-Dueñas, Víctor|||0000-0001-7834-2965
  • Goudet, Cyril|||0000-0002-8255-3535
  • Nonell, Santi|||0000-0002-8900-5291
  • Nicoletti, Ferdinando|||0000-0003-0917-443X
  • Llebaria, Amadeu|||0000-0002-8200-4827
  • Ciruela, Francisco|||0000-0003-0832-3739
Light-operated drugs constitute a major target in drug discovery, since they may provide spatiotemporal resolution for the treatment of complex diseases (i.e. chronic pain). JF-NP-26 is an inactive photocaged derivative of the metabotropic glutamate type 5 (mGlu) receptor negative allosteric modulator raseglurant. Violet light illumination of JF-NP-26 induces a photochemical reaction prompting the active-drug's release, which effectively controls mGlu receptor activity both in ectopic expressing systems and in striatal primary neurons. Systemic administration in mice followed by local light-emitting diode (LED)-based illumination, either of the thalamus or the peripheral tissues, induced JF-NP-26-mediated light-dependent analgesia both in neuropathic and in acute/tonic inflammatory pain models. These data offer the first example of optical control of analgesia in vivo using a photocaged mGlu receptor negative allosteric modulator. This approach shows potential for precisely targeting, in time and space, endogenous receptors, which may allow a better management of difficult-to-treat disorders.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Photomodulation of G protein-coupled adenosine receptors by a novel light-switchable ligand

  • Bahamonde, María Isabel
  • Taura, Jaume
  • Paoletta, Silvia
  • Gakh, Anadrei A.
  • Chakraborty, Saibal
  • Hernando, Jordi|||0000-0002-1126-4138
  • Fernández-Dueñas, Víctor|||0000-0001-7834-2965
  • Jacobson, Kenneth A.|||0000-0001-8104-1493
  • Gorostiza, Pau|||0000-0002-7268-5577
  • Ciruela, Francisco|||0000-0003-0832-3739
The adenosinergic system operates through G protein-coupled adenosine receptors, which have become promising therapeutic targets for a wide range of pathological conditions. However, the ubiquity of adenosine receptors and the eventual lack of selectivity of adenosine-based drugs have frequently diminished their therapeutic potential. Accordingly, here we aimed to develop a new generation of light-switchable adenosine receptor ligands that change their intrinsic activity upon irradiation, thus allowing the spatiotemporal control of receptor functioning (i.e., receptor activation/inactivation dependent on location and timing). Therefore, we synthesized an orthosteric, photoisomerizable, and nonselective adenosine receptor agonist, nucleoside derivative MRS5543 containing an aryl diazo linkage on the N substituent, which in the dark (relaxed isomer) behaved as a full adenosine A receptor (AR) and partial adenosine A receptor (AR) agonist. Conversely, upon photoisomerization with blue light (460 nm), it remained a full AR agonist but became an AR antagonist. Interestingly, molecular modeling suggested that structural differences encountered within the third extracellular loop of each receptor could modulate the intrinsic, receptor subtype-dependent, activity. Overall, the development of adenosine receptor ligands with photoswitchable activity expands the pharmacological toolbox in support of research and possibly opens new pharmacotherapeutic opportunities.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Angiotensin II type 1/adenosine A receptor oligomers, a novel target for tardive dyskinesia

  • Oliveira, Paulo A. de|||0000-0002-0852-4920
  • Dalton, James A. R.|||0000-0002-5279-4581
  • López Cano, Marc|||0000-0001-8885-3726
  • Ricarte, Adrià
  • Morató, Xavier|||0000-0002-3012-2864
  • Matheus, Filipe C.
  • Cunha, Andréia S.
  • Müller, Christa E.
  • Takahashi, Reinaldo N.
  • Fernández-Dueñas, Víctor|||0000-0001-7834-2965
  • Giraldo, Jesús|||0000-0001-7082-4695
  • Prediger, Rui D.
  • Ciruela, Francisco|||0000-0003-0832-3739
Tardive dyskinesia (TD) is a serious motor side effect that may appear after long-term treatment with neuroleptics and mostly mediated by dopamine D receptors (DRs). Striatal DR functioning may be finely regulated by either adenosine A receptor (AR) or angiotensin receptor type 1 (ATR) through putative receptor heteromers. Here, we examined whether AR and ATR may oligomerize in the striatum to synergistically modulate dopaminergic transmission. First, by using bioluminescence resonance energy transfer, we demonstrated a physical ATR-AR interaction in cultured cells. Interestingly, by protein-protein docking and molecular dynamics simulations, we described that a stable heterotetrameric interaction may exist between ATR and AR bound to antagonists (i.e. losartan and istradefylline, respectively). Accordingly, we subsequently ascertained the existence of ATR/AR heteromers in the striatum by proximity ligation in situ assay. Finally, we took advantage of a TD animal model, namely the reserpine-induced vacuous chewing movement (VCM), to evaluate a novel multimodal pharmacological TD treatment approach based on targeting the ATR/AR complex. Thus, reserpinized mice were co-treated with sub-effective losartan and istradefylline doses, which prompted a synergistic reduction in VCM. Overall, our results demonstrated the existence of striatal ATR/AR oligomers with potential usefulness for the therapeutic management of TD.